Ozempic (semaglutide) is an injectable GLP-1 receptor agonist that the Food and Drug Administration (FDA) approved to improve blood sugar levels in adults with type 2 diabetes
GLP-1 drugs have been shown to support sustained weight loss by reducing appetite and food intake 4
In contrast to these findings, 8 weeks of progressive RT (3 sets of 812 climbs, 50%100% of MCL) on alternating days in aging rats observed increased hippocampal protein expression of TNF- and IL-1 (Vilela et al., 2017)
Alprazolam does not affect GLP-1 receptors, and Wegovy does not influence GABA neurotransmission
In the UK, the approved maintenance dose is 5 mg, 10 mg, 15 mg once weekly
In addition to taking Ozempic, it is important to also maintain a healthy lifestyle that includes a balanced diet and regular exercise